Citadel Advisors’s Vivos Therapeutics VVOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-16
Closed -$136 – 15315
2023
Q1
$136 Sell
16
-120
-88% -$2.62K ﹤0.01% 14570
2022
Q4
$1.37K Buy
+136
New +$1.99K ﹤0.01% 14482
2022
Q1
– Sell
-1,636
Closed -$92K – 14681
2021
Q4
$92K Sell
1,636
-60
-4% -$4.83K ﹤0.01% 12798
2021
Q3
$171K Buy
+1,696
New +$178K ﹤0.01% 12201

Other funds holding VVOS

Citadel Advisors's VVOS Position: Q3 2026 in Review

Citadel Advisors opened a new position in Vivos Therapeutics (VVOS) in Q3 2026: 491,378 shares worth $72.7K. The stake represents ﹤0.01% of the portfolio and ranks #13142 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VVOS as recently as Q4 2022.

Citadel Advisors first reported a position in VVOS in Q1 2021 and has held it in 6 quarters since. The position peaked at $320K in Q3 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q3 2026.

  • Citadel Advisors held 491,378 shares of Vivos Therapeutics worth $72.7K as of Q3 2026.
  • Vivos Therapeutics was a new Citadel Advisors position in Q3 2026.
  • Vivos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13142 holding.
  • Citadel Advisors first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Citadel Advisors's Vivos Therapeutics position peaked at $320K in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.